Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
IdorsiaXSWX:IDIA -4.80%48 Operating Cash Flow per Share is CHF-0.48 as of Jun. 2026. GuruFocus rates XSWX:IDIA with a GF Score™ of 48/100 and a GF Value™ of CHF2.33 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 1,130 Biotechnology companies, Idorsia ranks better than 82.57% on this metric.
Idorsia's operating cash flow per share for the
three
months ended in Jun. 2026 was CHF-0.13.
Idorsia's operating cash flow per share for the trailing twelve months (TTM) ended in Jun. 2026 was CHF-0.48.
During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 47.20% per year.
During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 21.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.
The historical rank and industry rank for Idorsia's Operating Cash Flow per Share or its related term are showing as below:
XSWX:IDIA'
s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -17.8 Med: -9.3 Max: 47.2
Current: 47.2
During the past 10 years, Idorsia's highest 3-Year average Operating Cash Flow per Share Growth Rate was 47.20% per year. The lowest was -17.80% per year. And the median was -9.30% per year.
XSWX:IDIA's 3-Year OCF Growth Rate is ranked better than 82.57% of 1130
companies
in the Biotechnology industry
Industry Median: 16.85
vs XSWX:IDIA: 47.20
Idorsia Operating Cash Flow per Share Related Terms
Idorsia Operating Cash Flow per Share Historical Data
* Premium members only.
The historical data trend for Idorsia's Operating Cash Flow per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:IDIA vs VRTX, REGN, MRNA: Operating Cash Flow per Share Comparison
For the Biotechnology subindustry, Idorsia's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Idorsia Price-to-Operating-Cash-Flow vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Idorsia's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Idorsia's Price-to-Operating-Cash-Flow falls into.
Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF-0.48
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Operating Cash Flow per Share of CHF-0.48 mean?
Idorsia (XSWX:IDIA) has a Operating Cash Flow per Share of CHF-0.48 as of Jun. 2026. Operating cash flow per share equals the per-share amount of cash flow from operations. View historical data on Idorsia and its competitors. According to the industry distribution chart, Idorsia ranks #197 out of 1130 companies in the Biotechnology industry, placing it in the top 17.4%.
Is Idorsia's Operating Cash Flow per Share too high?
Idorsia's current Operating Cash Flow per Share is CHF-0.48. Based on the distribution chart, Idorsia ranks #197 out of 1130 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Idorsia has a GF Score™ of 48/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Idorsia's Operating Cash Flow per Share compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Idorsia ranks #197 out of 1130 companies for Operating Cash Flow per Share. This places Idorsia in the top 17% of its industry — outperforming the majority of peers. The industry median Operating Cash Flow per Share is 16.85. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Cash Flow per Share for a Biotechnology company?
The median Operating Cash Flow per Share among Biotechnology companies is 16.85, based on 1,130 companies in the industry. Companies in the top quartile (top 25%) have a Operating Cash Flow per Share significantly above this median, while those in the bottom quartile fall well below. However, Operating Cash Flow per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Cash Flow per Share mean?
A high Operating Cash Flow per Share can signal that a stock is expensive relative to its fundamentals. Operating cash flow per share equals the per-share amount of cash flow from operations. View historical data on Idorsia and its competitors. For the Biotechnology industry, the median Operating Cash Flow per Share is 16.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Idorsia's current Operating Cash Flow per Share is CHF-0.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Idorsia stock overvalued right now?
Based on GuruFocus' analysis, Idorsia (XSWX:IDIA) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF2.33, compared to a current price of CHF4.76 — trading 104.2% above its estimated fair value. The current Operating Cash Flow per Share is CHF-0.48. Idorsia's overall GF Score™ is 48/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Cash Flow per Share calculated?
Operating Cash Flow per Share is calculated from a company's financial statements. For Idorsia (XSWX:IDIA), the current Operating Cash Flow per Share is CHF-0.48 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Idorsia (XSWX:IDIA) Overvalued in 2026?
Based on GuruFocus' analysis, Idorsia stock appears to be overvalued.
The current stock price of CHF4.76 is trading 104.2% above its estimated GF Value™ of CHF2.33.
GuruFocus considers Idorsia to be Significantly Overvalued.
Key valuation signals for XSWX:IDIA:
Operating Cash Flow per Share: CHF-0.48
GF Value™: CHF2.33 vs. price of CHF4.76 (104.2% above fair value)
No single metric tells the full story. See the XSWX:IDIA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Idorsia Ltd is a biopharmaceutical company engaged in discovering, developing, and commercializing of medicines for unmet medical needs. The company is a biotech hub of Europe specialized in the discovery and development of small molecules, to provide new therapeutic options. The company focuses on multiple therapeutic areas which include the central nervous system, cardiovascular disorders, immunological disorders, and orphan diseases. The company's development compounds target a number of different diseases such as Resistant Hypertension, lupus, insomnia, Cerebral vasospasm, and Fabry disease. Geographically, it derives revenue from Switzerland.
48GF Score
Get the complete analysis for XSWX:IDIA
Operating Cash Flow per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:IDIA has been successfully added to your 
